KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
about
Primary Tumor Versus Liver-First Strategy in Patients with Stage IVA Colorectal Cancer: A Propensity Score Analysis of Long-term Outcomes and Recurrence Pattern.Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery.Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases.The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.Assessment of Overall Survival Benefits in Patients Undergoing Complete Hepatectomy for Synchronous Colorectal Cancer With Liver and Lung Metastases.
P2860
KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
KRAS Mutation Status Predicts ...... ocation of the Primary Lesion.
@en
type
label
KRAS Mutation Status Predicts ...... ocation of the Primary Lesion.
@en
prefLabel
KRAS Mutation Status Predicts ...... ocation of the Primary Lesion.
@en
P2093
P2860
P50
P1476
KRAS Mutation Status Predicts ...... ocation of the Primary Lesion.
@en
P2093
Junichi Shindoh
Masaji Hashimoto
Ryuji Yoshioka
Toshitaka Sugawara
Yujiro Nishioka
P2860
P2888
P304
P356
10.1245/S10434-016-5087-5
P577
2016-01-19T00:00:00Z
P6179
1017912579